Bristol-Myers Squibb Company (BMY) Position Held by Glenmede Trust Co. NA
Glenmede Trust Co. NA held its position in Bristol-Myers Squibb Company (NYSE:BMY) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 351,835 shares of the biopharmaceutical company’s stock at the close of the first quarter. Glenmede Trust Co. NA’s holdings in Bristol-Myers Squibb were worth $20,560,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of BMY. Welch Investments LLC increased its position in Bristol-Myers Squibb by 3.9% during the 1st quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock valued at $115,000 after purchasing an additional 79 shares during the period. Crestwood Advisors Group LLC purchased a new position in Bristol-Myers Squibb during the 1st quarter valued at about $116,000. Blue Chip Partners Inc. increased its position in Bristol-Myers Squibb by 0.8% during the 1st quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 17 shares during the period. State of Alaska Department of Revenue increased its position in Bristol-Myers Squibb by 2.8% during the 1st quarter. State of Alaska Department of Revenue now owns 2,229 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 60 shares during the period. Finally, Heritage Trust Co purchased a new position in Bristol-Myers Squibb during the 1st quarter valued at about $123,000. 68.80% of the stock is currently owned by institutional investors and hedge funds.
In other news, Director Theodore R. Samuels II bought 6,000 shares of the firm’s stock in a transaction dated Wednesday, August 2nd. The stock was acquired at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the acquisition, the director now owns 18,000 shares of the company’s stock, valued at $1,006,920. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the sale, the senior vice president now owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by insiders.
A number of research analysts have commented on BMY shares. Vetr raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $62.23 target price on the stock in a research report on Wednesday, July 12th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $63.00 target price on shares of Bristol-Myers Squibb in a research report on Wednesday, August 9th. BMO Capital Markets reissued an “underperform” rating and set a $47.00 target price (down previously from $51.00) on shares of Bristol-Myers Squibb in a research report on Wednesday, July 26th. BidaskClub raised shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. Finally, Leerink Swann cut their price objective on shares of Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating on the stock in a research report on Friday, July 28th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and ten have issued a buy rating to the stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average target price of $62.54.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/11/bristol-myers-squibb-company-bmy-position-held-by-glenmede-trust-co-na.html.
Bristol-Myers Squibb Company (NYSE BMY) traded down 0.42% during midday trading on Monday, hitting $62.36. 2,736,019 shares of the stock were exchanged. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $63.47. The firm has a 50-day moving average price of $57.59 and a 200-day moving average price of $55.71. The stock has a market cap of $102.27 billion, a P/E ratio of 22.78 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The business had revenue of $5.14 billion during the quarter, compared to analysts’ expectations of $5.09 billion. During the same quarter in the previous year, the business earned $0.69 EPS. The company’s revenue for the quarter was up 5.6% on a year-over-year basis. On average, equities research analysts anticipate that Bristol-Myers Squibb Company will post $2.98 EPS for the current fiscal year.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.